Molecular Mechanisms of Pharmacological Action Clinical Trials

8 recruiting

Molecular Mechanisms of Pharmacological Action Trials at a Glance

8 actively recruiting trials for molecular mechanisms of pharmacological action are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Bethesda, Arlington, and Aventura. Lead sponsors running molecular mechanisms of pharmacological action studies include National Institute of Mental Health (NIMH), Merz North America, Inc., and Merz Aesthetics GmbH.

Browse molecular mechanisms of pharmacological action trials by phase

Treatments under study

About Molecular Mechanisms of Pharmacological Action Clinical Trials

Looking for clinical trials for Molecular Mechanisms of Pharmacological Action? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Molecular Mechanisms of Pharmacological Action trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Molecular Mechanisms of Pharmacological Action clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

Molecular Mechanisms of Pharmacological ActionDepressive SymptomsSuicide+17 more
National Institute of Mental Health (NIMH)500 enrolled1 locationNCT06462196
Recruiting
Phase 2

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

DepressionDepressive DisorderMolecular Mechanisms of Pharmacological Action+10 more
National Institute of Mental Health (NIMH)50 enrolled1 locationNCT06511908
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz North America, Inc.300 enrolled28 locationsNCT07122193
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz Aesthetics GmbH300 enrolled26 locationsNCT07210463
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Phase 4

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

ConfusionCognitive DysfunctionMolecular Mechanisms of Pharmacological Action+14 more
Sunnybrook Health Sciences Centre2,400 enrolled8 locationsNCT04289142
Recruiting
Phase 1

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

MelanomaNeoplasmsNeoplasms by Site+7 more
Yana Najjar50 enrolled2 locationsNCT04572451
Recruiting
Phase 4

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Breast CancerHeart FailureBreast Diseases+10 more
Silesian Centre for Heart Diseases600 enrolled4 locationsNCT05465031